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This brief review explores some recent observations relating to the structure of 
untransformed glucocorticoid and progesterone receptors and the mechanism by 
which the receptors are transformed to the DNA-binding state. In their molybdate- 
stabilized, untransformed state, progesterone and glucocorticoid receptors exist as 
a heteromeric 8-9s complex containing one unit of steroid binding phosphoprotein 
and one or two units of the 90 kD heat shock protein hsp90. When the receptors 
are transformed, the steroid-binding protein dissociates from hsp90. In cytosol 
preparations, temperature-mediated dissociation proceeds much more rapidly in 
the presence of hormone. The dissociated receptor binds to DNA with high 
affinity, regardless of whether it is in the hormone-bound or the hormone-free 
state. These observations raise the possibility that the primary, and perhaps the 
only, role for the hormone is to promote dissociation of the receptor-hsp90 
complex. 
Molybdate, vanadate, and tungstate inhibit receptor transformation to the 
DNA-binding form, an effect that appears to reflect the ability of these transition 
metal oxyanions to stabilize the complex between the steroid receptor and hsp90. 
By promoting the formation of disulfide bonds, hydrogen peroxide also stabilizes 
the glucocorticoid receptor-hsp90 complex and prevents receptor transformation. 
A small, heat-stable factor present in all cytosol preparations inhibits receptor 
transformation, and, when the factor is removed, glucocorticoid receptors are 
rapidly transformed. This ubiquitous factor has the physical properties of a metal 
anion, and it is proposed that molybdate and vanadate affect steroid receptor 
complexes by interacting with a metal anion-binding site that is normally occupied 
by this endogenous receptor-stabilizing factor. 
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When steroid-bound receptors in cell-free lysates are exposed to increases in 
temperature, ionic strength, or pH, the receptors are transformed from a non-DNA- 
binding state to a form that binds to nuclei, DNA, and a variety of polyanions 111. 
For a long time, analysis of the structure of the untransformed, non-DNA-binding 
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state of glucocorticoid and progesterone receptors was compromised by the fact that 
the procedures employed for analysis of receptor structure promote receptor transfor- 
mation. The study of the transformation process was facilitated when it was shown 
that molybdate, a transition metal oxyanion known to stabilize the steroid-binding 
activity of unoccupied glucocorticoid receptors 121, could reversibly inhibit transfor- 
mation of steroid-bound receptors [3,4; see 5,6, for reviews]. 
Several laboratories have examined the structure of molybdated-stabilized glu- 
cocorticoid receptors by molecular sieve chromatography and sucrose gradient cen- 
trifugation. It was established that glucocorticoid receptors that are stabilized in their 
untransformed state exist in cytosol preparations as oligomeric complexes with an 
apparent M, of about 300,000, and that, during transformation to the DNA-binding 
state, the receptor undergoes a reduction in size to an apparent M, of 94,000-100,000 
[7-91. The untransformed complex is the 8-9s complex, and the dissociated, trans- 
formed state is the classic 4s form of the receptor.* Careful analysis of the size of 
molybdate-stabilized receptors for other steroids [6,10,11] has led to a general model 
in which the untransformed receptor exists in cytosol preparations as a large oligo- 
meric complex and the DNA-binding form is the dissociated receptor protein. Hol- 
brook et a1 [7] have shown that glucocorticoid receptors that were transformed in 
intact cells and subsequently analyzed in the presence of molybdate sediment at about 
4S, whereas untransformed receptors sediment at 9 s  under the same conditions. This 
suggests that transformation in intact cells is also accompanied by a reduction in 
receptor size and that molybdate may be stabilizing a physiologically relevant complex. 
PURIFICATION OF UNTRANSFORMED RECEPTORS 
When affinity resins for steroid receptor isolation were developed in the early 
1980s, several investigators used the technique to purify the untransformed, molyb- 
date-stabilized form of progesterone and glucocorticoid receptors. In the case of both 
the progesterone receptor from the chick oviduct [12,13] and the glucocorticoid 
receptor from mouse L cells [ 141 or rat liver [ 151, the major protein that was purified 
was an 85-92 kD (now referred to as 90 kD) protein. The purified progesterone 
[ 12,131 and glucocorticoid [ 15,161 receptors sedimented as 8-9s complexes in the 
presence of molybdate, and, afier withdrawal of molybdate, they dissociated to 4s 
complexes in the presence of salt. Because the 90 kD protein was not recovered when 
cytosol was preincubated with steroid in order to occupy receptor sites prior to 
adsorption with the affinity resin [14,15,17], it was assumed that the 90 kD protein 
was the steroid-binding protein. 
Subsequently, when radiolabeled, site-specific affinity ligands were used to 
identify the steroid-binding component of the purified molybdate-stabilized progester- 
one receptor complex, it became clear that the 90 kD protein was not labeled. In the 
case of the chick oviduct, two proteins were labeled with the progesterone analog 
*In this review, I refer to the untransformed molybdate-stabilized glucocorticoid and progesterone 
receptor complexes as migrating at 9s on sucrose gradient centrifugation and the dissociated state of the 
receptors as migrating at 4s. Various authors have utilized more specific values (eg, 9.2S, 8.5, 4.5S, 
3.8s) based on analysis with their own systems, but, for the purposes of this discussion, such distinctions 
are not necessary. 
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[3H]R5020, one that migrated on gel electrophoresis under denaturing conditions at 
approximately 80 kD and another that migrated at about 110 kD [17,18]. These 
steroid-binding proteins correspond, respectively, to the A and B peptides character- 
ized previously on purification of the transformed progesterone receptor from chick 
oviduct [ 191. Affinity purification of the molybdate-stabilized rabbit uterine proges- 
terone receptor yielded 85 and 120 kD steroid-binding proteins and a 90 kD nonster- 
oid-binding protein [20]. 
Careful examination of the purified molybdate-stabilized receptor from mouse 
L cells and WEHI-7 thymoma cells revealed a 100 kD protein that was labeled with 
the affinity ligand [3H]dexamethasone 21-mesylate and a 90 kD nonsteroid-binding 
phosphoprotein [21,22]. Although it is clear that most of the 90 kD material purified 
from molybdate-stabilized rat liver cytosol is not a steroid-binding protein [ 161, it has 
proved difficult to resolve clearly the nonsteroid-binding component from the intact 
rat liver glucocorticoid-binding protein, which migrates close to it at 94 kD [23]. 
EVIDENCE THAT THE 90 kD PROTEIN IS A COMPONENT OF 9s RECEPTOR 
COMPLEXES 
The 90 kD protein can be clearly differentiated from the progesterone- and 
glucocorticoid-binding proteins on the basis of its immunoreactivity . Radanyi et a1 
[24] prepared a monoclonal antibody (BF4) to the purified, molybdate-stabilized 
chicken oviduct progesterone receptor and showed that it reacted with the 90 kD 
nonsteroid-binding protein but not with the 80 kD or the 110 kD progesterone-binding 
proteins [25]. Similarly, antiserum raised against the purified 110 kD progesterone- 
binding protein recognizes the 80 and 110 kD steroid-binding peptides but not the 90 
kD peptide [26]. Sullivan et a1 [27] have also prepared several monoclonal antibodies 
against the progesterone receptor-associated 90 kD protein from chick oviduct. None 
of these antibodies bind to the transformed 4 s  form of the progesterone receptor, but 
two of them bind to the untransformed 9 s  complex. Importantly, the BF4 antibody of 
Radanyi et a1 [24] has been demonstrated to react with (shift the sedimentation 
velocity of) molybdate-stabilized estrogen, androgen, and glucocorticoid receptor 
complexes in chick oviduct cytosol [28] and mineralocorticoid receptors in cytosol 
from chick colon [29]. Similarly, the CBl antibody of Sullivan et a1 [27] was shown 
to react with untransformed androgen and glucocorticoid receptors in chick oviduct 
When untransformed glucocorticoid receptors are immunopurified (by adsorp- 
tion to protein A-Sepharose) from molybdate-stabilized cytosol using monoclonal 
antibodies specific for the 100 kD steroid-binding protein, the 90 kD nonsteroid- 
binding protein is also absorbed in an immunospecific manner [21,22]. Immunoad- 
sorption of transformed receptors does not result in isolation of the 90 kD protein 
[22,30-321. The 90 kD protein is clearly a component of the 9s receptor complex; 
immunoadsorption of the isolated 9 s  complex from L cells with antibody specific for 
the 90 kD protein results in the immunospecific adsorption of the 100 kD glucocorti- 
coid-binding protein [33]. 
All of these observations have led to a general model in which the molybdate- 
stabilized, untransformed state of glucocorticoid and progesterone receptors contains 
a 90 kD nonsteroid-binding protein in addition to a steroid-binding protein. Given 




receptors, it is likely that the 90 kD protein is a component of untransformed estrogen, 
androgen, and mineralocorticoid complexes as well. 
It is of considerable interest that, in the presence of molybdate, the receptor for 
the fungal sex steroid pheromone antheridiol in cytosol of Achlyu urnbisexualis male 
cells has a sedimentation coefficient of 8 s  [34]. As with other steroid receptors, the 
8s form can be converted to the 4s form by salt treatment [35]. Riehl et al [36] have 
purified an 88 kD protein that is associated with the molybdate-stabilized antheridiol- 
binding protein and prepared a monoclonal antibody called AC88. This AC88 anti- 
body recognizes an epitope common to a 90 kD protein present in cytosols prepared 
from a wide range of tissues obtained from a number of avian and mammalian species 
[36]. The observations made on fungal antheridiol receptors suggest that the associa- 
tion of steroid-binding proteins with the 90 kD protein has been conserved throughout 
evolution of eukaryotes from fungi to the highly evolved mammals. The fact that 
AC88 antibody recognizes an epitope that is conserved in 90 kD proteins present in 
cytosols prepared from all vertebrate tissues tested suggests that the 90 kD protein is 
ubiquitous and essential to cell function. 
THE 90 kD PROTEIN ASSOCIATED WITH STEROID RECEPTORS IS A 
HEAT SHOCK PROTEIN 
By 1985, several facts about the 90 kDa receptor-associated protein were 
known. 1) As noted above, it contains a region that is conserved in 90 kD proteins 
that are widely distributed in vertebrate tissues [27,36,37]. 2) It is phosporylated on 
serine residues by intact cells [14,21,22,38,39]. 3) It is located largely in the 
cytoplasm as shown by immunohistochemical analysis [37]. 4) It is an abundant 
protein in cytosol preparations [30,36,40]. These characteristics taken together are 
descriptive of the 90 kD heat shock protein [41,42], so hsp90 was considered a likely 
candidate for the receptor-associated protein. Accordingly, three laboratories working 
with the receptor-associated 90 kD protein (the laboratories of Toft, Baulieu, and 
Pratt) formed collaborations with laboratories working with hsp90 (those of Brugge, 
Feramisco, and Schlesinger, respectively) to determine if the 90 kD receptor-associ- 
ated protein is hsp90. 
Identity of the progesterone receptor-associated 90 kD protein of chick oviduct 
was established by several criteria [40,43]. 1) The receptor-associated protein was 
shown to have the same peptide map as hsp90. 2) Monoclonal antibody directed 
against hsp90 recognized the receptor-associated protein in immunoblot assay. 3) 
Anti-hsp90 antibody caused a shift in the sedimentation of the molybdate-stabilized 
receptor. 4) A monoclonal antibody against the receptor-associated protein recognized 
a 90 kD protein whose rate of synthesis increased when chick embryo fibroblasts 
were heat shocked. Similarly, the glucocorticoid receptor-associated 90 kD protein of 
L cell cytosol was shown to react on immunoblot assay with antibody raised against 
purified chicken heat shock protein [30,31], and the same antibody was used to 
immunoadsorb the 100 kD glucocorticoid-binding protein from the isolated molyb- 
date-stabilized 9 s  complex [33]. 
Taken together, these observations provide strong evidence that untransformed 
progesterone and glucocorticoid receptors are associated with hsp90 in a heterooli- 
gomeric 9 s  complex. The stoichiometry of the components is not yet firmly estab- 
lished. Okret et a1 [44] have provided good evidence that the molybdate-stabilized rat 
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liver glucocorticoid receptor complex contains only one molecule of the steroid- 
binding protein. Renoir et al [ 171 have employed a cross-linlung technique to examine 
the molybdate-stabilized progesterone receptor purified from chick oviduct cytosol, 
and they suggest a stoichiometry of one molecule of steroid-binding protein to two 
molecules of hsp90. It is tempting to add up the molecular masses involved to try to 
account for a 9s complex. For the glucocorticoid receptor, for example, one steroid- 
binding progein and two units of hsp90 would yield a complex of M, about 280,000, 
which is close to several estimates for the mass of the molybdate-stabilized receptor 
[7-91. It should be emphasized, however, that there is no proof for such a composi- 
tion, and other, as yet unidentified components could exist in the heteromeric, 
untransformed receptor complex. 
DISSOCIATION OF THE RECEPTOR FROM hsp90 DURING 
TRANSFORMATION 
The fact that hsp90 has been recovered in association with the untransformed, 
9S, non-DNA-binding form of progesterone and glucocorticoid receptors but not in 
association with the 4S, DNA-binding form suggests that dissociation of receptor 
from hsp90 is critical for generating the DNA-binding state. Several observations 
support the proposal that dissociation from hsp90 is closely linked to and perhaps 
sufficient for generating transformed receptor. The observation of Mendel et a1 [22] 
that hsp90 is not associated with glucocorticoid receptors that have undergone steroid- 
dependent transformation in intact mouse thymoma cells (whereas it is readily re- 
covered in association with untransformed receptors) provides evidence that dissocia- 
tion is relevant to hormone-dependent events as they occur in intact cells. 
Most of the information regarding dissociation of receptor from hsp90 has been 
generated in cell-free lysates. When L cell cytosol is incubated at 25°C in the absence 
of molybdate, receptors are transformed to the DNA-binding state, they are converted 
from the 9s to the 4s form, and they dissociate from hsp90. As was demonstrated 
by Sanchez et a1 [32], temperature-mediated transformation, 9s to 4 s  conversion, 
and dissociation from hsp90 are all hormone-promoted events in that they proceed 
much more rapidly under hypotonic conditions when the receptor is bound by 
glucocorticoid. Correspondingly, Renoir has demonstrated that it is very difficult to 
separate untransformed, RU486-bound rabbit progesterone receptors from hsp90, 
regardless of whether the liganded receptor is exposed to elevated temperature or salt 
(J.-M. Renoir, personal communication). It is possible that the physiological action 
of RU486, which in many systems is a pure progesterone and glucocorticoid antago- 
nist [45,46], can be explained by its failure to permit receptor dissociation from 
hsp90. Indeed, RU486 appears to increase the affinity of the receptor for the large- 
M, complex in rabbit uterine cytosol. 
At this point, one might ask what is the role of the steroid in glucocorticoid 
hormone action? Traditionally, it has been thought that steroid must be bound to the 
receptor for the receptor to be biologically active. It is possible, however, that the 
only role played by the steroid in the sequence of events leading to high-affinity 
association of receptors with nuclear “acceptor” sites in the cell is to permit temper- 
ature-mediated receptor transformation. If, as I have indicated in the model shown in 
Figure 1, dissociation of the receptor from hsp90 is sufficient for transformation to 
the DNA-binding state, then hormone-free receptors that have been separated from 
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Fig. 1 .  Model illustrating the components of untransformed and transformed glucocorticoid receptor 
and the dissociation of the subunits during transformation. The receptor-bound steroid is indicated by 
the hexagon on the phosphoprotein containing the metal-binding site. The 9s untransformed complex 
contains one unit of the glucocorticoid-binding phosphoprotein and one or two units of the 90 kD heat 
shock protein hsp90. The open circles with question marks indicate that there might be other, as yet 
unidentified components in the untransformed complex. The presence of a metal anion (Me2-)-binding 
site is indicated in the steroid-binding protein. Both the endogenous inhibitor of transformation and the 
transition metal oxyanions molybdate and vanadate may interact at this site to maintain the receptor in 
high-affinity association with hsp90. During transformation, the steroid-binding protein dissociates from 
hsp90, resulting in exposure of the DNA-binding domain. The presence of sulfhydryl groups (SH) is to 
indicate that SH moieties are absolutely required for the glucocorticoid receptor to bind steroid and for 
the transformed receptor to bind to DNA. Different SH groups are required for steroid binding and 
DNA binding, and that is indicated in the model. (Reproduced from Meshinchi et a1 [92] with permission 
of the publisher.) 
hsp90 should bind to DNA. The hsp90-receptor complex is readily dissociated with 
salt, and the resulting dissociated glucocorticoid receptor is precipitated at 30-35 % 
ammonium sulfate [47]. In contrast, hsp90 does not precipitate until ammonium 
sulfate is present at 60-70% of saturation. When ammonium sulfate (40-50%) is 
added to L cell cytosol containing hormone-free glucocorticoid receptors in the 
absence of molybdate, the receptor dissociates from hsp90 and it precipitates, leaving 
all the hsp90 in the supernatant [32]. The redissolved hormone-free receptor binds 
very tightly to DNA-cellulose. Indeed, we see no difference between hormone-free 
and steroid-bound receptor with regard to DNA-binding affinity. 
Willmann and Beato [48] have recently shown that the steroid-free glucocorti- 
coid receptor of rat liver binds selectively to hormone regulatory elements (HRE) in 
the long terminal repeat (LTR) region of mouse mammary tumor virus (MMTV) 
DNA. Bailly et a1 [49] have demonstrated that HRE sites located upstream from the 
start site of the rabbit uteroglobin gene are occupied with similar affinity by purified 
rabbit uterine progesterone receptors regardless of whether the receptors are hor- 
mone-free, or complexed with agonist, or complexed with the antagonist RU486. 
Taken together, these observations suggest that the steroid is not required for 
DNA binding by the receptor once it is dissociated from the other components of the 
9s cytosolic complex. In vivo, the hormone is clearly required to produce a hormone 
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response, and it has been shown by the genomic footprinting technique to be required 
for protein-DNA interactions that occur at a glucocorticoid response element (GRE) 
[50]. It has not be demonstrated, however, that the hormone must be bound to the 
receptor for the receptor to interact appropriately with high-affinity nuclear “accep- 
tor” sites and modulate gene transcription. Indeed, it is possible that in intact cells 
the receptor-mediated effects of glucocorticoids and progestins follow as a conse- 
quence of a steroid-dependent dissociation of the receptor from an hsp90-containing 
structure(s) that serves to keep the receptor from association with “acceptor” sites in 
the absence of hormone. 
Now that techniques are available to identify receptors in the absence of ligand, 
it has become clear that hormone-free glucocorticoid receptors undergo some trans- 
formation when cytosol preparations are incubated at 25°C. It had not been possible 
to detect this transformation previously because the unbound receptors lose their 
steroid-binding capacity when dissociation occurs. With immunoblot experiments 
[32] and with the DNaseI footprinting technique [48], it has been shown that some 
unoccupied receptor is converted to the DNA-binding form on incubation of cytosol 
at 25 “C. Thus, under cell-free conditions in cytosol preparations, the glucocorticoid 
does not act as an absolute switch to permit a receptor transformation that cannot 
occur in its absence. Rather, the hormone seems to increase markedly the rate of the 
temperature-dependent dissociation process, The rate at which receptor dissociation 
and generation of the DNA-binding state occurs in the absence of steroid seems to 
vary somewhat from one system to another. In mouse L cell cytosol, for example, 
hormone-free transformation occurs very slowly [32], but in rat liver cytosol it occurs 
considerably more rapidly [48] (also, work in progress by Bresnick and Pratt). 
RECEPTOR PHOSPHORYLATION IN RELATION TO RECEPTOR 
TRANSFORMATION 
As the change in sedimentation value of the receptor from 9s to 4 s  and 
dissociation of receptor from hsp90 are both promoted by glucocorticoid when cytosol 
is warmed at 25”C, the binding of the steroid must somehow reduce the affinity of 
the receptor for association with other components of the complex. In cytosol prepa- 
rations, the effect of the steroid is not simply to change an equilibrium; the untrans- 
formed 9s complex is not generated from the 4 s  transformed state on elimination of 
steroid. The experiments of Raaka and Samuels [51] suggest that untransformed 
receptors are rapidly generated from transformed receptors in intact cells incubated 
at 37°C. The unidirectional nature of the transformation process in cytosol prepara- 
tions may suggest that some component of the 9s complex is limiting such that 
reassociation cannot occur. It is also possible that the receptor has undergone some 
covalent change that makes it unable to reassociate. 
Both glucocorticoid [ 14,21,22] and progesterone receptors [17,38,52,53] are 
naturally phosphorylated in intact cells, and several laboratories have suggested that 
transformation of the receptor to the DNA-binding form may require its dephosphor- 
ylation [1,54-57]. There are examples in which the DNA-binding activity of DNA- 
binding proteins is affected by phosphorylation [see, eg, 58,591, but the data available 
suggest that a change in phosphorylation state is not required for generation of a 
DNA-binding form of either glucocorticoid or progesterone receptors. 
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Smith et a1 [60] have carefully examined both the size and the PI of glucocorti- 
coid receptors from IM-9 human lymphoblasts to determine if transformation involves 
covalent charge modification. The [3H]dexamethasone-labeled steroid-binding protein 
of IM-9 cells resolves into two isoforms of identical mass. After transformation, there 
is no change in the apparent PI of either isoform, indicating that there is no covalent 
charge modification of the glucocorticoid-binding protein. It has been reported that 
treatment of untransformed glucocorticoid receptors with alkaline phosphatase pro- 
motes transformation [56,57], an effect that could reflect an action of the enzyme on 
the steroid-binding protein, on hsp90, or perhaps on other components of cytosol. 
Smith et a1 [ a ]  have treated immunoadsorbed IM-9 receptor with alkaline phospha- 
tase and found no change in the PI of either isoform of the steroid-binding protein. It 
is interesting that, after thermal transformation, only the more basic of the two 
steroid-binding protein isoforms binds to DNA-cellulose. 
Mendel et a1 [61] and Tienrungroj et a1 [62,63] have directly examined 32P- 
labeled mouse glucocorticoid receptors before and after transformation in intact cells 
and found no change in the degree of phosphorylation of the steroid-binding protein. 
There is also no evidence for a change in the phosphorylation state of the glucocorti- 
coid-binding protein after thermal transformation of receptors in cytosol prepared 
from L cells [62]. Careful experiments have determined that the glucocorticoid- 
binding protein of mouse thymoma cells (WEHI-7) contains two or three phosphory- 
lation sites per steroid binding site [61]. With this limited number of phosphorylated 
sites, changes at one site should be readily detectable. The results of experiments in 
which the 32P-labeled L cell receptor was submitted to limited proteolysis suggest 
that the 16 kD trypsin fragment containing the DNA-binding domain is phosphory- 
lated, whereas the 28 kD fragment containing the steroid-binding domain is not [63]. 
At this time, however, there is no evidence to support a model in which phosphory- 
lation of the glucocorticoid receptor, either within the DNA-binding domain or 
elsewhere, affects its DNA-binding activity [60-631. 
Three laboratories have examined the relationship between progesterone-bind- 
ing protein phosphorylation and transformation. Garcia et a1 [53] identified the 
presence of the 32P-labeled 110 kD progesterone-binding protein (“B” unit) in cytosol 
prepared from estrogen-treated chick oviduct cells grown in the presence of 
[32P]orthophosphate in culture. After the intact cells were incubated with progester- 
one, the 100 kD binding protein could be identified in salt extracts of nuclei by 
immunoblot analysis, but no radioactivity could be demonstrated in the nuclear 
receptor. Logeat et a1 [52] examined the phosphorylation state of progesterone 
receptors in rabbit uterine slices incubated with [32P]orthophosphate. In the absence 
of hormone, the cytosolic receptor was phosphorylated, but, in contrast to the 
observations of Garcia et a1 [53], in the presence of hormone, phosphorylation was 
markedly enhanced in receptors recovered from nuclei. Toft’s laboratory (D .O. Toft, 
personal communication) has confirmed the observation of Logeat et a1 with proges- 
terone receptors in chick oviduct minces, where exposure of cells to hormone rapidly 
increases the extent of phosphorylation and decreases the electrophoretic mobility of 
progesterone-binding protein recovered in the cytosolic fraction. 
Thus it appears that association of progesterone with receptors in intact cells 
leads to an increase in phosphorylation of progesterone-binding proteins. The receptor 
is phosphorylated prior to exposure to hormone, and it appears that the increased 
phosphorylation in the presence of hormone is due to phosphorylation at a supplemen- 
8:SHA 
Steroid Receptor Transformation JCB:59 
tary site or sites. It is possible that the site(s) that is phosphorylated on the progester- 
one-binding protein is made available for phosphorylation when the receptor 
dissociates from hsp90. There is, as yet, no indication that phosphorylation is required 
for progesterone receptor transformation or that it affects the ability of the trans- 
formed receptor to bind to DNA. Indeed, Badly et al 1491 have shown that progester- 
one receptors isolated either from rabbit uterine cytosol before hormone-dependent 
phosphorylation or from nuclei after hormone-dependent phosphorylation bind with 
the same affinity to DNA that contains hormone-responsive elements. 
RECEPTOR OXIDATION AND REDUCTION IN RELATION TO RECEPTOR 
TRANSFORMATION 
In contrast to the data available regarding phosphorylation, it is clear that 
disulfide bond formation markedly affects the ability of glucocorticoid receptors to 
undergo 9 s  to 4s dissociation and transformation to the DNA-binding form. Sulfhy- 
dry1 groups clearly play an important role in determining the functional state of 
glucocorticoid receptors. Sulfhydryl groups are absolutely required for maintaining 
the receptors in an appropriate conformation for binding of glucocorticoids [a-671. 
Treatment of transformed glucocorticoid-receptor complexes with several types of 
sulfhydryl-modifying reagents inactivates their DNA-binding activity without causing 
steroid dissociation [68], and Bodwell et al [69] have provided good evidence that the 
sulfhydryl moieties required for DNA binding by the transformed receptor are 
different from those required for steroid binding by the untransformed receptor. 
Using sulfhydryl-modifying reagents, it has been difficult to determine whether 
sulfhydryl moieties are involved in receptor dissociation and transformation. Young 
et al[70] reported that iodoacetamide inhibits DNA binding of glucocorticoid-receptor 
complexes, but, because the sulfhydryl-reacting reagent was present during the 
transforming procedure, it was not possible to determine whether the reagent inhibited 
transformation to the DNA-binding state, or whether it inhibited DNA binding by 
transformed receptors, or whether it inhibited both processes. Kalimi and Love [71] 
reexamined the question and concluded that iodoacetamide and N-ethylmaleimide 
inhibited the transformation event and not DNA binding. Bodwell et a1 [68] were not 
able to reach a conclusion whether treatment of untransformed glucocorticoid-recep- 
tor complexes interferes with the transformation process. 
Rather than using sulfhydryl-derivatizing agents, Tienrungroj et a1 [72] asked 
whether promoting oxidation of sulfhydryl moieties with hydrogen peroxide would 
inhibit the transformation event. It is clear that the presence of hydrogen peroxide 
during 25°C incubation of rat liver or L cell cytosols containing glucocorticoid- 
receptor complexes prevents conversion of receptors from 9s to 4 s  and dissociation 
of the receptor from hsp90. If dithiothreitol is added to reverse the peroxide effect 
and cytosol is incubated a second time at 25"C, hsp90 dissociates, and the receptor is 
converted to the 4S, DNA-binding form. The transformation that occurs during the 
second incubation in the presence of the thiol-disulfide exchange reagent dithiothreitol 
is both temperature-dependent and inhibited by molybdate. These observations argue 
rather strongly that there are critical sulfur moieties in the untransformed receptor 
complex that must be in a reduced form for temperature-mediated receptor dissocia- 
tion and transformation to occur. 
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It should be noted that treatment of rat Dunning prostate tumor cytosol with 
cupric phenanthroline, a reagent that promotes disulfide bond formation, prevents 
dissociation of the 10s receptor complex by 0.4 M salt 1731. Similarly, peroxide 
prevents the dissociation of hsp90 that occurs when L cell glucocorticoid receptors 
immunoadsorbed to protein A-Sepharose are washed with 0.4 M NaCl [72]. At this 
time, it is not known if peroxide and cupric phenanthroline are promoting the 
formation of a disulfide bond(s) between the steroid-binding protein and another 
protein with which it is associated or whether they promote intramolecular disulfide 
bond formation. It is also not known whether the sulkydryl groups required for 
receptor dissociation are the same as or different from those required for receptor 
binding to DNA. It should be noted that peroxide produces the same effects as 
molybdate, vanadate, and tungstate on glucocorticoid receptors. 
Experiments with sulfhydryl-modifying reagents demonstrate that a sulfhydryl 
group (or groups) is required for binding of progesterone to receptor in chick oviduct 
cytosol [74,75]. Iodoacetamide was also shown to inhibit temperature-mediated gen- 
eration of the DNA-binding state, but the experimental protocol did not unequivocally 
distinguish between an effect on transformation and an effect on the DNA-binding 
activity of the transformed receptor [75]. In 1982, MacDonald and Leavitt [76] 
reported that thiol-disulfide exchange reagents such as dithiothreitol promote transfor- 
mation of progesterone receptors in hamster uterine cytosol . Optima1 transformation 
(up to 75% of total steroid-bound receptor) occurred when cytosol was diluted in 
buffer in the presence of dithiothreitol. They suggested that the untransformed 
progesterone receptor was associated with an inhibitor (M, > 30,000) that dissociated 
from the receptor on transformation in a manner that was promoted by disulfide bond 
reduction. They were unable to determine whether the sulfur moieties important for 
transformation were located in the receptor or in the inhibitor or whether they were 
involved in a disulfide bridge between the two. The observations of MacDonald and 
Leavitt [76] might be readily explained if the redox state of the hamster uterine 
cytosol in the absence of reducing agent was such that a disulfide bridge could form 
between the steroid-binding protein and hsp90. 
From cloning and sequencing, it is known that glucocorticoid [77] and proges- 
terone [78] receptors (as well as all the other steroid receptors) contain multiple 
cysteine residues, several of which are located in the DNA-binding domain in vicinal 
thiol arrangements that provide optimal metal-binding ligands and sites for thiol- 
disulfide interchange. In that various of the cysteine moieties in the receptor must be 
in thiol form for the untransformed receptor complex to bind steroid, for the receptor 
to dissociate from hsp90 during transformation, and for the transformed receptor to 
bind to DNA, it seems quite clear that sulkydryl groups are critical for receptor 
function. The possibility that some of these functions of the receptor are naturally 
regulated via thiol-disulfide interchange is intriguing and deserves further research. 
Kaufmann et a1 [79] have provided evidence that glucocorticoid receptors are associ- 
ated with nuclear matrix as a result of disulfide bond formation. This raises the 
possibility that promotion of disulfide bond formation can be used to identify proteins 
neighboring the transformed receptor located in nuclear acceptor sites as well as 
proteins neighboring the receptor in its untransformed state in the cell. 
INHIBITION OF RECEPTOR TRANSFORMATION BY METALS 
The group VI-A transition metal oxyanions molybdate, vanadate, and tungstate 
appear to inhibit glucocorticoid-receptor transformation by inhibiting the dissociation 
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of the steroid-binding protein from hsp90 [30-32,801. Although the ability of molyb- 
date to affect glucocorticoid receptor function was discovered serendipitously during 
experiments in which it was being used as a phosphatase inhibitor 12,811, its ability 
to inhibit receptor transformation is unrelated to phosphatase inhibition [see 5 ,  for 
review]. This is inferred from the fact that it stabilizes receptors to dissociation by 
physical methods, such as by salt (eg, NaC1, ammonium sulfate [4,32,47,82]), by 
alkaline pH, and by dilution, as well as by the fact that it stabilizes highly purified 
progesterone and glucocorticoid receptors in their 9s form [ 12,13,15,16]. 
It is possible that molybdate interacts exclusively with the steroid-binding 
protein to increase its affinity for other components of the 9s complex. Alternatively, 
it could form some sort of bridge structure, such as that envisioned by Wilson et a1 
[73], between the steroid-binding protein and hsp90. A concentration of 0.5-1 .O mM 
molybdate or 0.2 mM vanadate is required to produce half-maximal stabilization of 
untransformed glucocorticoid and progesterone receptors in cytosol at physiological 
pH [ 10,821, and, at these concentrations, the metal oxyanions do not affect the binding 
of transformed receptors to DNA. The functional groups required for molybdate 
interaction with the receptor are unknown. It should be noted, however, that molyb- 
date and vanadate have a well established avidity for sulfur [83] and that they can 
form bridge structures between adjacent sulfhydryl moieties [84,85]. One can specu- 
late that potential metal binding vicinal cys-Xz-cys arrangements in the receptor [ 861 
provide the ligands with which the transition metal oxyanions interact to produce 
their stabilizing effects. It is also interesting to speculate that molybdate, vanadate, 
and tungstate may stabilize the untransformed receptor by interacting with the binding 
site for an endogenous metal component of the untransformed receptor-hsp90 complex. 
The existence of an endogenous inhibitor of transformation was first suggested 
by the laboratories of Litwack et a1 [87,88] and Milgrom et a1 1891, who noted that 
separation of glucocorticoid-receptor complexes from low-M, components of rat liver 
cytosol by dilution or gel filtration caused enhanced binding to nuclei and DNA- 
cellulose. Transformation was prevented if the low-M, components were added back 
to the treated receptor preparation. The transformation-inhibiting factor was found to 
be stable to boiling and to have an M, of < 1,500 [87-891. Sat0 et a1 [90] subsequently 
reported that removal of a low-M, inhibitor by dialysis of rat uterine or ventral 
prostate cytosol caused estrogen and androgen receptors to transform to a state that 
bound to isolated nuclei. Readdition of the inhibitor prevented further transformation. 
These observations led to the concept that untransformed receptors in cytosol are 
stabilized by a low-M, endogenous factor and that, on removal of this factor, receptors 
are rapidly transformed. 
In 1982, Leach et a1 [91] set up an assay in which rat liver cytosol was diluted 
and then returned to original volume by filtration through an Amicon filter that 
excludes molecules with an M, greater than about 10,OOO. In this “filtered” cytosol, 
high-M, components, such as the glucocorticoid receptor and hsp 90, are present at 
the same concentration as in normal cytosol, but low-M,, filterable components are 
present at about one-sixth their concentration in normal cytosol. Receptors in filtered 
cytosol are transformed rapidly at 15”C, and addition of boiled rat liver cytosol 
inhibits the transformation in a concentration-dependent manner. Using this system, 
it was shown that cytosols prepared from a wide variety of rodent and human tissues, 
as well as from avians and amphibians and from primitive eukaryotes like lobster and 
yeast, all contain a heat-stable factor that inhibits the receptor transformation [91]. 
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The inhibitor is effective when it is present at the concentration at which it is normally 
present in unfiltered cytosol. This heat-stable factor was partially purified from boiled 
rat liver cytosol. The factor was found to be anionic at physiological pH and to be 
unaffected by incubation with a wide variety of hydrolytic enzymes. 
Meshinchi et a1 [92] have demonstrated that this apparently ubiquitous factor 
produces all the known effects of molybdate on glucocorticoid receptors. 1) It inhibits 
temperature- and salt-mediated receptor transformation. 2) It inhibits loss of steroid- 
binding activity caused by warming cytosol containing unoccupied receptors. 3) It 
stabilizes the oxidized, nonsteroid-binding form of the receptor to irreversible tem- 
perature-mediated inactivation of steroid binding activity. 4) It inhibits temperature- 
and salt-mediated dissociation of receptor to the 4 s  form. 5 )  It inhibits dissociation of 
the receptor from hsp90. Because a substantial fraction of the bioactivity of the factor 
survives heating at 700°F for 2 hr and all the bioactivity is eliminated by passing the 
factor through a column of Chelex 100, it is highly likely that the endogenous factor 
is a metal. The factor behaves as a strong anion with an apparent M, of 340 by 
chromatography on Bio-Gel P-2, where it elutes in the same fractions as molybdate 
or vanadate. The factor binds to hydroxylapatite and is retained by a sulfhydryl- 
cellulose matrix. The latter may indicate that the metal anion has an avidity for sulfur, 
although this has not been proved; it has not yet been determined if derivatization of 
the sulfhydryl moieties prevents adsorption of the factor to the column matrix. 
Thus the endogenous factor not only produces all the known effects of molyb- 
date and vanadate on receptor function but it also has the same size, charge, and 
chelation properties as these metal oxyanions. Because the receptor dissociates rapidly 
when cytosol is depleted of the factor, it is reasonable to propose that the factor 
normally interacts with the receptor to account for the stability of the large-M,, 
untransformed complex in cytosol preparations. It is not an unreasonable speculation 
that molybdate and vanadate affect steroid-receptor complexes by interacting with a 
metal anion binding site that is normally occupied by this endogenous receptor- 
stabilizing factor. In the model shown in Figure 1, it is indicated that cysteine moieties 
in the steroid-binding protein may contribute the ligands that determine such a metal 
anion-binding site. 
SOME THOUGHTS REGARDING THE RECEPTOR-hSp9O COMPLEX 
Although a complex between hsp90 and steroid receptors can be readily dem- 
onstrated in cell-free lysates, it has not been proved that the existence of the complex 
is relevant to hormone action in intact cells. Some investigators have questioned 
whether the complex with the heat shock protein is an artifact resulting from the use 
of steroid-affinity resins [93] or from the use of molybdate to stabilize receptors in 
their 9S, untransformed state [94]. Several observations argue against such an artifact. 
1) The complex has been demonstrated by immunological as well as steroid-affinity 
methods [27,28,30]. 2) Steroid receptors were demonstrated to exist as 9s complexes 
in cell-free lysates many years prior to the discovery of molybdate effects [95]. 
Molybdate stabilizes receptors in their 9s form but does not promote the formation 
of 9s complexes from the dissociated 4s form. 4) Although molybdate is helpful, it 
is not required to visualize the complex between hsp90 and either the progesterone 
[27,40,96] or the glucocorticoid receptor [62]. 5)  Molybdate has been shown to 
inhibit nuclear accumulation of glucocorticoid- and estrogen-receptor complexes in 
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intact cells while simultaneously increasing the recovery of the 9s complex [97]. The 
latter observation, combined with the observation that dissociation of glucocorticoid 
receptors from hsp90 is promoted by hormone in intact cells [22], supports the 
intracellular existence and physiological relevance of a receptor-hsp90 complex. 
A major problem in determining the physiological relevance of steroid-receptor 
association with hsp90 is that the function of this ubiquitous and abundant cytoplasmic 
protein is unknown [98,99]. The rate of its synthesis is increased by heat shock [ 1001, 
and its synthesis is depressed during glucose deprivation [loll. It is interesting to 
note that, in L cells deprived of glucose, glucocorticoids selectively increase the rate 
of hsp90 synthesis [ 1021. Although it is normally located in the cytoplasm, hsp89 (the 
avian homolog of the mammalian hsp90) becomes associated with the nucleus when 
heat-shocked chick embryo cells are restressed [99]. This association with nuclear 
structure is noncovalent, since it is completely disrupted by mild detergent lysis [99]. 
These observations with the avian heat shock protein raise the possibility that mam- 
malian hsp90 is associated with structural components of the cell and is subject to 
similar relocation. In this respect, it is interesting to note that hsp90 has the ability to 
bind to purified F-actin in a Ca2+-calmodulin-regulated manner [ 103,1041, suggesting 
that it might associate with an actin-containing structure(s) in intact cells. 
The fact that hsp90 exists in cells from primitive eukaryotes to humans and is 
part of the heat shock response suggests a function essential to cell survival [41,42]. 
In that hsp90 is present in great abundance with respect to steroid receptors, it is clear 
that it must perform a more general function in the regulation of cellular events. It is 
known that the Rous sarcoma virus tyrosine kinase pp6OSrc binds transiently to hsp90 
[ 105,1061, as do some other avian sarcoma virus-transforming proteins [ 107,1081. 
The reason for this association is not known, but it is interesting that a temperature- 
sensitive mutant pp6OS" binds with high affinity to hsp90 at nonpermissive tempera- 
ture. The complex of pp6OSrc with hsp90 includes a third protein of M, 50,000 whose 
function is unknown. 
As has been noted above and elsewhere 1961, there is a distinct possibility that 
the 9s steroid receptor complex contains another component or components. It is 
important to note that a monoclonal antibody prepared against the molybdate-stabi- 
lized 9s rabbit progesterone receptor recognizes an epitope on a 59 kD protein 
[109,110]. The 59 kD protein appears to be associated with hsp90, and the antibody 
against the 59 kD protein causes the immunospecific absorption of androgen, estro- 
gen, glucocorticoid, and progesterone receptors from rabbit uterine or liver cytosol 
[lll].  Peptide mapping suggests that the 59 kD protein is a protein structurally 
different from hsp90, raising the possibility that it is a third component of 9s steroid- 
receptor complexes. 
If steroid receptors interact with hsp90 in a physiologically significant way in 
intact cells, then it should be possible to mutate receptor genes and alter both steroid 
response and association with hsp90. Giguere et a1 [112] have constructed a variety 
of insertional mutants of the human glucocorticoid-receptor gene that have permitted 
the definition of at least four functional domains in the receptor protein. If the 
association of receptor with hsp90 is important for maintaining the receptor in an 
inactive form in the absence of hormone in intact cells, then one can predict that at 
least one structural feature required for high-affinity association with hsp90 lies within 
the steroid-binding domain. Three observations support this prediction. 1) Gehring 
and Arndt [113] have demonstrated that glucocorticoid receptors of the nt' type from 
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a steroid-resistant mutant line of S49.1 lymphoma cells exist in their untransformed, 
molybdate-stabilized state as 9s complexes. The nt' receptor consists of the carboxyl- 
terminal 40 kD peptide, which contains both the steroid-binding and DNA-binding 
domains [ 1141. Gehring and Arndt [ 1131 also demonstrated that incubation of molyb- 
date-stabilized, wild-type S49 cell receptors with chymotrypsin yields 9 s  complexes 
in which the steroid-binding protein has been cleaved to about 40 kD. Mendel et a1 
[ 1151 have made similar observations with receptors in rat thymocyte cytosol. It may 
be inferred from these observations that the 40 kD carboxyl portion of the steroid- 
binding protein is sufficient for creating the 9 s  heteromeric complex [113], and it is 
not likely that the 50 kD amino segment plays a critical role in recognizing hsp90. 2) 
Miesfeld et a1 [ I161 have demonstrated that carboxyl-terminal deletions of the rat 
glucocorticoid-receptor gene produce receptors that no longer require hormone bind- 
ing for enhancer activation. Thus these truncated receptors, which lack the steroid- 
binding domain, function as constitutive activators. If association with hsp90 main- 
tains the receptor in an inactive form in the absence of hormone, then a site that is 
responsible for determining the receptor-hsp90 complex must lie somewhere within 
(or very near) the steroid-binding domain. 3) If the model is a general one in the 
sense that hsp90 associates with a variety of steroid receptors, then the receptors 
should contain a common structural feature within the steroid-binding domain. As 
was noted by Danielson et a1 [117], there is a 20-amino-acid region of strong 
homology that lies within the C-terminal domain of the mouse glucocorticoid receptor 
(amino acids 583-602) and the human estrogen receptor (361-380). The same region 
exists between amino acids 729 and 748 of the rabbit progesterone receptor [118]. 
Danielson et a1 [ 1171 have speculated that this region is involved in receptor transfor- 
mation and that alterations in the region might result in a receptor that does not 
associate with hsp90 and is transcriptionally active in the absence of hormone. 
One of the more intriguing questions raised by the model presented in Figure 1 
relates to how hormone binding might trigger dissociation of the receptor-hsp90 
complex. It is possible that the binding of the steroid changes the confirmation of the 
receptor in the region that determines binding to hsp90. Another possibility is that the 
steroid indirectly alters the affinity of the receptor for hsp90 by affecting the binding 
site for an endogenous metal anion that stabilizes the receptor-hsp90 complex. As is 
indicated in the model, when an endogenous metal anion is removed from cytosol, 
the glucocorticoid receptor dissociates from hsp90. The binding of the steroid might 
reduce the affinity of the steroid-binding protein for the metal component through an 
allosteric mechanism or possibly by affecting the redox state of the metal-binding 
ligands. 
If the association of the glucocorticoid receptor with hsp90 in the intact cell 
determines whether the receptor is subsequently recovered in the cytosolic or nuclear 
fraction after cell lysis, then a recent experiment by Mendel et a1 [I191 suggests that 
dissociation from hsp90 can occur in the absence of hormone. It has been known for 
many years that cells exposed to energy-limiting conditions, such as glucose limitation 
and anaerobiosis, rapidly lose their ability to bind glucocorticoids [ 120- 1221. Both 
the loss of binding capacity and its recovery when the metabolic blockade is overcome 
are unaffected by inhibitors of protein synthesis [82,122], implying that receptor 
turnover is not responsible for the loss and return of steroid-binding capacity. It was 
assumed that the receptor was probably present in a nonhormone-binding state in 
cytosol prepared from such ATP-depleted cells. Using the Western blot procedure, 
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Mendel et al [ 1191 have shown that glucocorticoid receptors become tightly bound to 
nuclei when mouse thymoma cells are depleted of ATP by treatment with dinitrophe- 
no1 in the absence of hormone. It is not clear how this shift of receptor to the nuclear 
fraction occurred. It may be that the effects of dinitrophenol on cellular metabolism 
somehow disrupted the receptor-hsp90 complex and the receptor was then able to 
associate with normal nuclear “acceptor” sites, or it may be that the effects of 
dinitrophenol treatment provoked the formation of disulfide bonds between the recep- 
tor and nuclear components or between the receptor and cellular structural elements 
that are recovered in the nuclear fraction. Exposure of cells to dinitrophenol is an 
excellent method of generating a heat shock response [42], and the change in receptor 
localization could be related in some way to the cellular stress response. At this time, 
it is possible that the observation of Mendel et al [ 1191 reflects hormone-free transfor- 
mation of glucocorticoid receptors in intact cells. 
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